{"log_id": 2917097283900565372, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0, "average": 0.999107, "min": 0.999107}, "location": {"width": 22, "top": 158, "height": 58, "left": 1168}, "words": "家"}, {"probability": {"variance": 0.002886, "average": 0.98081, "min": 0.704169}, "location": {"width": 781, "top": 224, "height": 27, "left": 234}, "words": "不明确。美托洛尔不改变文拉法辛或其活性代谢产物ODV的药代动力学特性。当合并使用"}, {"probability": {"variance": 1e-06, "average": 0.99904, "min": 0.9976}, "location": {"width": 259, "top": 271, "height": 25, "left": 235}, "words": "美托洛尔和文拉法辛时应谨慎"}, {"probability": {"variance": 7e-05, "average": 0.996713, "min": 0.955859}, "location": {"width": 734, "top": 315, "height": 26, "left": 280}, "words": "在某些患者中,文拉法辛治疗与血压升高呈剂量相关性。建议患者在服用本品时应定"}, {"probability": {"variance": 0.000276, "average": 0.992178, "min": 0.940633}, "location": {"width": 216, "top": 361, "height": 26, "left": 235}, "words": "期监测血压(见【警告】"}, {"probability": {"variance": 0.000142, "average": 0.986864, "min": 0.974948}, "location": {"width": 42, "top": 410, "height": 23, "left": 237}, "words": "锂盐"}, {"probability": {"variance": 0.006235, "average": 0.979253, "min": 0.502341}, "location": {"width": 734, "top": 451, "height": 27, "left": 279}, "words": "12名健康志愿者单剂量口服600mg锂盐时,对服用文拉法率150mg/天并达到稳态的药"}, {"probability": {"variance": 0.000651, "average": 0.991109, "min": 0.852262}, "location": {"width": 672, "top": 497, "height": 27, "left": 236}, "words": "动学不受影响,锂盐对ODV的代谢也无影响。文拉法辛对锂盐的代谢也无影响"}, {"probability": {"variance": 8e-06, "average": 0.997626, "min": 0.992248}, "location": {"width": 222, "top": 543, "height": 24, "left": 237}, "words": "血浆蛋白结合率高的药物"}, {"probability": {"variance": 0.000389, "average": 0.993455, "min": 0.88055}, "location": {"width": 731, "top": 585, "height": 27, "left": 284}, "words": "文拉法辛是一个蛋白结合率较低的药物,因此,本品不干扰其它蛋白结合率高的药物"}, {"probability": {"variance": 0.0042, "average": 0.970541, "min": 0.825631}, "location": {"width": 121, "top": 633, "height": 25, "left": 235}, "words": "游离浓度升高"}, {"probability": {"variance": 0.001927, "average": 0.980669, "min": 0.787243}, "location": {"width": 526, "top": 675, "height": 25, "left": 241}, "words": "干扰凝血的药物(例如非甾体性抗炎药、阿司匹林和华法令)"}, {"probability": {"variance": 0.004952, "average": 0.985415, "min": 0.564305}, "location": {"width": 730, "top": 719, "height": 26, "left": 287}, "words": "血小板5-羟色胺释放在凝血过程中发挥重要作用。流行病学研究证明这些药物与精神"}, {"probability": {"variance": 0.002415, "average": 0.983629, "min": 0.718617}, "location": {"width": 779, "top": 763, "height": 29, "left": 237}, "words": "治疗药物联用可以干扰5-羟色胺的再摄取,显示非体性抗炎药或阿司匹林与精神药物合并"}, {"probability": {"variance": 0.001743, "average": 0.983527, "min": 0.823549}, "location": {"width": 778, "top": 807, "height": 29, "left": 237}, "words": "使用可能产生上胃肠道出血的风险。在SRIs和 SNRIS药物与华法令合并使用时,有报道改"}, {"probability": {"variance": 0.001599, "average": 0.987268, "min": 0.764573}, "location": {"width": 728, "top": 852, "height": 30, "left": 238}, "words": "变抗凝效应,包括出血的增加。使用华法令的患者开始或中断本品治疗时应仔细监测"}, {"probability": {"variance": 2.2e-05, "average": 0.997156, "min": 0.984593}, "location": {"width": 259, "top": 899, "height": 25, "left": 238}, "words": "其他可能影响文拉法辛的药物"}, {"probability": {"variance": 3.5e-05, "average": 0.99687, "min": 0.977565}, "location": {"width": 231, "top": 944, "height": 25, "left": 283}, "words": "文拉法辛的代谢通路包括C"}, {"probability": {"variance": 0.006773, "average": 0.963471, "min": 0.582237}, "location": {"width": 402, "top": 943, "height": 23, "left": 611}, "words": "P3A4。文拉法辛主要由细胞色素P450CYP2D6"}, {"probability": {"variance": 0.002415, "average": 0.983497, "min": 0.744236}, "location": {"width": 780, "top": 986, "height": 27, "left": 238}, "words": "酶代谢为活性的代谢产物ODV。相对于CYP2D6,CYP3A4在文拉法辛的代谢过程中是"}, {"probability": {"variance": 4e-06, "average": 0.9984, "min": 0.994895}, "location": {"width": 82, "top": 1034, "height": 23, "left": 238}, "words": "次要通路"}, {"probability": {"variance": 0.000187, "average": 0.9851, "min": 0.960531}, "location": {"width": 142, "top": 1077, "height": 24, "left": 241}, "words": "CYP2D6抑制剂:"}, {"probability": {"variance": 0.000252, "average": 0.98373, "min": 0.967866}, "location": {"width": 161, "top": 1049, "height": 60, "left": 795}, "words": "生药"}, {"probability": {"variance": 0.020301, "average": 0.947809, "min": 0.377078}, "location": {"width": 699, "top": 1108, "height": 38, "left": 282}, "words": "体外和在体的研究证实文拉法辛主要由CYP2D6酶代谢为有性的谢产物O"}, {"probability": {"variance": 0.003979, "average": 0.974002, "min": 0.694478}, "location": {"width": 778, "top": 1161, "height": 28, "left": 238}, "words": "CYP2D6酶对多种抗抑郁药的代谢活性决定于基因多态性。当交拉法辛和CYP2D6抑制剂"}, {"probability": {"variance": 0.010372, "average": 0.964349, "min": 0.390065}, "location": {"width": 776, "top": 1207, "height": 27, "left": 241}, "words": "合用时,可能会降低文拉法辛代谢成为ODV,结果导致文拉法血药浓度升高,ODV的浓"}, {"probability": {"variance": 0.009012, "average": 0.970654, "min": 0.45193}, "location": {"width": 780, "top": 1249, "height": 32, "left": 240}, "words": "度降低。这种作用与CYP2D6酶低活性的人群代邀特征相似(见【药代动力学嘉代谢和排"}, {"probability": {"variance": 0.001007, "average": 0.986101, "min": 0.837453}, "location": {"width": 776, "top": 1295, "height": 30, "left": 242}, "words": "泄)。由于文拉法辛和ODV均具有药理适性,因此当文拉法辛和抑制CYP2D6的药物合用"}, {"probability": {"variance": 4.3e-05, "average": 0.99418, "min": 0.981999}, "location": {"width": 141, "top": 1344, "height": 24, "left": 240}, "words": "时无需调整剂量"}, {"probability": {"variance": 0.001947, "average": 0.966064, "min": 0.872201}, "location": {"width": 137, "top": 1391, "height": 23, "left": 242}, "words": "CYP3A抑制剂"}, {"probability": {"variance": 0.01043, "average": 0.969339, "min": 0.379907}, "location": {"width": 757, "top": 1430, "height": 30, "left": 242}, "words": "合并使用CYP3A4抑制剂和文拉法辛可能会升高文拉法辛和ODV水平(见康唑)。因此"}, {"probability": {"variance": 0.000462, "average": 0.98761, "min": 0.902613}, "location": {"width": 378, "top": 1476, "height": 26, "left": 242}, "words": "当CYP3A4抑制剂和文拉法辛合用时应谨慎"}, {"probability": {"variance": 0.012309, "average": 0.946351, "min": 0.504906}, "location": {"width": 267, "top": 1512, "height": 23, "left": 242}, "words": "CYP2D6和CYP3A4双重抑制剂"}], "language": 3}